Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.41 | 10.38 | 15.88 | 5.14 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.00) | (5.40) | (8.53) | (3.30) | |
P/B ratio |
5.79 | 0.00 | 0.00 | 4.40 | |
Price to Tangible BV |
5.81 | 0.00 | 0.00 | 4.41 | |
EV/Sales |
0.53 | 8.70 | 12.48 | (0.29) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.04 | |
EV/Operating CF |
(0.06) | (1.17) | (1.70) | 0.04 | |
EV/FCF |
(0.06) | (1.11) | (1.62) | 0.04 | |
Quick Ratio |
0.87 | 1.29 | 1.78 | 2.43 | |
Current Ratio |
0.98 | 1.55 | 1.93 | 2.62 | |
Net Debt/EBITDA |
0.98 | 1.48 | 2.03 | 2.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.25 | 0.23 | 0.16 | 0.14 | |
Operating CF/Net income |
(0.46) | (0.98) | 0.36 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.05) | |
Research and Development Expense of Revenue |
316.76% | 846.94% | 1,067.40% | 1,217.98% | |
Selling, General and Administrative Expense of Revenue |
106.68% | 240.97% | 234.00% | 229.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.60% | 59.73% | 46.14% | 39.08% | |
Graham Net Nets |
(0.18) | (0.25) | (0.28) | 0.14 | |
Graham Number |
0.00 | 2.86 | 5.07 | 0.00 | |
Earnings Yield |
(461.54%) | (110.32%) | (112.00%) | (170.54%) | |
Free Cash Flow Yield |
(637.72%) | (75.37%) | (48.39%) | (145.82%) | |
Revenue per Share |
0.04 | 0.02 | 0.02 | 0.04 | |
Operating CF per Share |
(0.13) | (0.23) | (0.23) | (0.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.23) | (0.23) | (0.39) | |
Cash per Share |
0.11 | 0.24 | 0.47 | 1.48 | |
Shareholders Equity per Share |
0.02 | (0.26) | (0.51) | 0.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.02 | (0.26) | (0.51) | 0.29 | |
Free Cash Flow |
(9.81) | (17.66) | (17.75) | (14.25) | |
Working Capital |
(0.21) | 7.82 | 18.87 | 35.86 | |
Capital Expenditures |
— | — | — | (0.01) | |
Net Current Asset Value |
(1.79) | (23.51) | (42.59) | 6.47 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.04 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 1.29 | |
Average Payables |
7.12 | 4.30 | 7.02 | 5.71 | |
Average Assets |
27.64 | 40.81 | 58.46 | 64.97 | |
Average Common Equity |
8.37 | 5.12 | 0.29 | 26.44 |
Columns are period end dates